[go: up one dir, main page]

MX2016009468A - Polisacaridos capsulares de streptococcus pneumoniae y conjugados de los mismos. - Google Patents

Polisacaridos capsulares de streptococcus pneumoniae y conjugados de los mismos.

Info

Publication number
MX2016009468A
MX2016009468A MX2016009468A MX2016009468A MX2016009468A MX 2016009468 A MX2016009468 A MX 2016009468A MX 2016009468 A MX2016009468 A MX 2016009468A MX 2016009468 A MX2016009468 A MX 2016009468A MX 2016009468 A MX2016009468 A MX 2016009468A
Authority
MX
Mexico
Prior art keywords
streptococcus pneumoniae
conjugates
capsular polysaccharides
pneumoniae capsular
polysaccharides
Prior art date
Application number
MX2016009468A
Other languages
English (en)
Other versions
MX371454B (es
Inventor
Krishna Prasad Avvari
Gu Jianxin
Kumar Kainthan Rajesh
Hwan Kim Jin-
Ying YANG Yu-
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MX2016009468A publication Critical patent/MX2016009468A/es
Publication of MX371454B publication Critical patent/MX371454B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/09Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092Streptococcus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/385Haptens or antigens, bound to carriers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0003General processes for their isolation or fractionation, e.g. purification or extraction from biomass
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00Preparation of compounds containing saccharide radicals
    • C12P19/04Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6037Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6068Other bacterial proteins, e.g. OMP
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Sustainable Development (AREA)
  • Molecular Biology (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se refiere a polisacáridos de serotipo 10A, 22F o 33F de Streptococcus pneumoniae activados y procesos para su preparación. La invención también se refiere a conjugados inmunogénicos que comprenden polisacáridos de serotipo 10A, 22F o 33F de Streptococcus pneumoniae covalentemente unidos a una proteína portadora, procesos para su preparación y composiciones inmunogénicas y vacunas que las comprenden.
MX2016009468A 2014-01-21 2015-01-15 Polisacaridos capsulares de streptococcus pneumoniae y conjugados de los mismos. MX371454B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461929598P 2014-01-21 2014-01-21
PCT/IB2015/050314 WO2015110940A2 (en) 2014-01-21 2015-01-15 Streptococcus pneumoniae capsular polysaccharides and conjugates thereof

Publications (2)

Publication Number Publication Date
MX2016009468A true MX2016009468A (es) 2016-10-13
MX371454B MX371454B (es) 2020-01-29

Family

ID=52630419

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016009468A MX371454B (es) 2014-01-21 2015-01-15 Polisacaridos capsulares de streptococcus pneumoniae y conjugados de los mismos.
MX2020001139A MX382438B (es) 2014-01-21 2015-01-15 Polisacaridos capsulares de streptococcus pneumoniae y conjugados de los mismos

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020001139A MX382438B (es) 2014-01-21 2015-01-15 Polisacaridos capsulares de streptococcus pneumoniae y conjugados de los mismos

Country Status (21)

Country Link
US (4) US10105431B2 (es)
EP (2) EP3096783B1 (es)
JP (4) JP6612260B2 (es)
KR (2) KR102049826B1 (es)
CN (3) CN112168957A (es)
AU (2) AU2015208820B2 (es)
BR (1) BR112016015835B1 (es)
CA (1) CA2937184A1 (es)
DK (1) DK3096783T3 (es)
ES (1) ES2883343T3 (es)
FR (1) FR22C1039I2 (es)
HK (1) HK1223273A1 (es)
HR (1) HRP20211337T1 (es)
HU (1) HUE055408T2 (es)
IL (5) IL283554B (es)
MX (2) MX371454B (es)
PL (1) PL3096783T3 (es)
PT (1) PT3096783T (es)
RU (1) RU2710393C2 (es)
SI (1) SI3096783T1 (es)
WO (1) WO2015110940A2 (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2937184A1 (en) * 2014-01-21 2015-07-30 Pfizer Inc. Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
US11160855B2 (en) * 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
MY192183A (en) 2015-07-21 2022-08-05 Pfizer Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
CA3005524C (en) * 2015-11-20 2023-10-10 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
AU2017306711B2 (en) 2016-08-05 2022-08-04 Sk Bioscience Co., Ltd. Multivalent pneumococcal polysaccharide-protein conjugate composition
TWI770044B (zh) 2016-08-05 2022-07-11 南韓商Sk生物科技股份有限公司 多價肺炎球菌多醣-蛋白質共軛物組成物(一)
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
MA47223A (fr) * 2016-12-30 2019-11-06 Sutrovax Inc Conjugués polypeptide-antigène avec des acides aminés non naturels
KR20240169144A (ko) 2017-01-31 2024-12-02 머크 샤프 앤드 돔 엘엘씨 다당류-단백질 접합체 제조 방법
US11090374B2 (en) 2017-02-24 2021-08-17 Merck Sharp & Dohme Corp. Enhancing immunogenicity of Streptococcus pneumoniae polysaccharide-protein conjugates
PT3585803T (pt) 2017-02-24 2025-12-22 Merck Sharp & Dohme Formulações de vacina pneumocócica conjugada
WO2018227177A1 (en) 2017-06-10 2018-12-13 Inventprise, Llc Multivalent conjugate vaccines with bivalent or multivalent conjugate polysaccharides that provide improved immunogenicity and avidity
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
FI3678654T3 (fi) * 2017-09-07 2024-09-02 Merck Sharp & Dohme Llc Pneumokokkipolysakkaridit ja niiden käyttö immunogeenisissä polysakkaridi-kantajaproteiini-konjugaateissa
CN116898959A (zh) 2017-09-07 2023-10-20 默沙东有限责任公司 肺炎球菌多糖及其在免疫原性多糖-载体蛋白缀合物中的用途
MX394767B (es) 2017-09-07 2025-03-24 Merck Sharp & Dohme Llc Polisacaridos neumococicos y su uso en conjugados de polisacarido inmunogenico con proteina transportadora.
US11524076B2 (en) * 2017-09-07 2022-12-13 Merck Sharp & Dohme Llc Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
US10246715B1 (en) * 2017-10-02 2019-04-02 National Health Research Institutes CpG-oligodeoxynucleotide, immunogenic composition including the same, and method of inducing immune response by the same
AU2018400751B2 (en) 2017-12-06 2022-07-21 Merck Sharp & Dohme Llc Compositions comprising Streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
AU2019215212B2 (en) 2018-02-05 2025-05-15 Sk Bioscience Co., Ltd. Multivalent pneumococcal polysaccharide-protein conjugate composition
KR20230008923A (ko) 2018-02-05 2023-01-16 사노피 파스퇴르 인코포레이티드 다가 폐렴구균성 다당류-단백질 접합체 조성물
EP3782642A4 (en) 2018-04-18 2022-04-13 SK Bioscience Co., Ltd. CAPSULE POLYSACCHARIDES FROM STREPTOCOCCUS PNEUMONIAE AND CONJUGATES THEREOF
JP7397000B2 (ja) 2018-04-30 2023-12-12 メルク・シャープ・アンド・ドーム・エルエルシー 凍結乾燥変異ジフテリア毒素のジメチルスルホキシド中均一溶液を提供する方法
CN112074294B (zh) 2018-04-30 2025-07-11 默沙东有限责任公司 从冻干球生产肺炎链球菌荚膜多糖载体蛋白缀合物的方法
JP7506605B6 (ja) 2018-04-30 2024-07-16 メルク・シャープ・アンド・ドーム・エルエルシー 肺炎球菌莢膜多糖類担体タンパク質複合体の製造方法
WO2020009993A1 (en) * 2018-07-04 2020-01-09 Sutrovax, Inc. Improvements in immunogenic conjugates
CA3120922A1 (en) * 2018-12-12 2020-06-18 Pfizer Inc. Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
GEAP202415690A (en) 2018-12-19 2024-01-10 Merck Sharp & Dohme Llc Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
JP7239509B6 (ja) 2019-02-22 2023-03-28 ファイザー・インク 細菌多糖類を精製するための方法
WO2021165847A1 (en) 2020-02-21 2021-08-26 Pfizer Inc. Purification of saccharides
EP3892260A1 (en) * 2020-04-10 2021-10-13 Bayer Animal Health GmbH Immunostimulatory compositions based on liposomes with zwiterionic and cationic lipids
US12053515B2 (en) 2020-08-10 2024-08-06 Inventprise, Inc. Multivalent pneumococcal glycoconjugate vaccines containing emerging serotype 24F
JP2023546446A (ja) 2020-10-22 2023-11-02 ファイザー・インク 細菌多糖を精製する方法
JP7804673B2 (ja) 2020-11-10 2026-01-22 ファイザー・インク コンジュゲートさせた莢膜糖抗原を含む免疫原性組成物およびその使用
CA3221075A1 (en) 2021-05-28 2022-12-01 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
AU2023385908A1 (en) 2022-11-22 2025-05-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
AU2024246082A1 (en) 2023-03-30 2025-10-16 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CN121057590A (zh) 2023-04-14 2025-12-02 辉瑞公司 包含缀合荚膜糖抗原的免疫原性组合物及其用途
WO2024224266A1 (en) 2023-04-24 2024-10-31 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2025057078A1 (en) 2023-09-14 2025-03-20 Pfizer Inc. Adjuvanted immunogenic compositions comprising conjugated pneumococcal capsular saccharide antigens and uses thereof
WO2025186705A2 (en) 2024-03-06 2025-09-12 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4709017A (en) 1985-06-07 1987-11-24 President And Fellows Of Harvard College Modified toxic vaccines
US4950740A (en) 1987-03-17 1990-08-21 Cetus Corporation Recombinant diphtheria vaccines
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
DE3841091A1 (de) 1988-12-07 1990-06-13 Behringwerke Ag Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
CA2006700A1 (en) 1989-01-17 1990-07-17 Antonello Pessi Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
FI920131A7 (fi) 1989-07-14 1992-01-13 American Cyanamid Co Sytokiini- ja hormonikantajia konjugaattirokotteita varten
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
DE69113564T2 (de) 1990-08-13 1996-05-30 American Cyanamid Co Faser-Hemagglutinin von Bordetella pertussis als Träger für konjugierten Impfstoff.
IL101715A (en) 1991-05-02 2005-06-19 Amgen Inc Recombinant dna-derived cholera toxin subunit analogs
US5371197A (en) * 1991-09-24 1994-12-06 Merck & Co., Inc. Protein-dimeric polysaccharide conjugate vaccine
WO1993013302A1 (de) 1991-12-23 1993-07-08 Michael Zoche Motor mit einer vorrichtung zur entölung
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
WO1993021769A1 (en) 1992-05-06 1993-11-11 President And Fellows Of Harvard College Diphtheria toxin receptor-binding region
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
DE69434079T2 (de) 1993-03-05 2005-02-24 Wyeth Holdings Corp. Plasmid zur Herstellung von CRM-Protein und Diphtherie-Toxin
US5917017A (en) 1994-06-08 1999-06-29 President And Fellows Of Harvard College Diphtheria toxin vaccines bearing a mutated R domain
US6455673B1 (en) 1994-06-08 2002-09-24 President And Fellows Of Harvard College Multi-mutant diphtheria toxin vaccines
CA2194761C (en) 1994-07-15 2006-12-19 Arthur M. Krieg Immunomodulatory oligonucleotides
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5565204A (en) * 1994-08-24 1996-10-15 American Cyanamid Company Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
JP2001513776A (ja) 1997-02-28 2001-09-04 ユニバーシティ オブ アイオワ リサーチ ファウンデーション LPS関連障害の処置における非メチル化CpGジヌクレオチドを含む核酸の使用
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
ATE370740T1 (de) 1997-05-20 2007-09-15 Ottawa Health Research Inst Verfahren zur herstellung von nukleinsäurekonstrukten
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
ATE356630T1 (de) 1998-04-03 2007-04-15 Univ Iowa Res Found Verfahren und produkte zur stimulierung des immunsystems mittels immunotherapeutischer oligonukleotide und zytokine
JP4673974B2 (ja) 1998-09-30 2011-04-20 ワイス・ホールディングズ・コーポレイション アジュバントとしての変異コレラホロトキシン
JP4689044B2 (ja) 1998-12-21 2011-05-25 メディミューン,インコーポレーテッド ワクチン用の肺炎連鎖球菌タンパク質と免疫原断片
KR100802198B1 (ko) 1998-12-23 2008-02-11 샤이어 바이오켐 인코포레이티드 신규한 스트렙토코커스 항원
HU229968B1 (hu) * 1999-03-19 2015-03-30 Smithkline Beecham Biologicals S.A Sztreptokokkusz oltóanyag
US6936258B1 (en) 1999-03-19 2005-08-30 Nabi Biopharmaceuticals Staphylococcus antigen and vaccine
WO2000061761A2 (en) 1999-04-09 2000-10-19 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
JP5051959B2 (ja) 2000-06-20 2012-10-17 アイディー バイオメディカル コーポレイション オブ ケベック ストレプトコッカス抗原
GB0108364D0 (en) * 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
AU2002309706A1 (en) 2001-05-11 2002-11-25 Aventis Pasteur, Inc. Novel meningitis conjugate vaccine
EP1404279A4 (en) 2001-06-07 2007-08-08 Wyeth Corp MUTANT FORMS OF CHOLERA HOLOTOXIN AS ADJUVANT
CN1297316C (zh) 2001-06-07 2007-01-31 惠氏控股有限公司 作为佐剂的霍乱全毒素的突变体形式
AU2002347404A1 (en) 2001-09-14 2003-04-01 Cytos Biotechnology Ag In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
AU2002351623A1 (en) 2001-12-20 2003-07-09 Shire Biochem Inc. Streptococcus antigens
US20040096461A1 (en) * 2002-07-30 2004-05-20 Baxter Healthcare Corporation Chimeric multivalent polysaccharide conjugate vaccines
CN101818185B (zh) 2003-03-13 2016-05-25 葛兰素史密丝克莱恩生物有限公司 纯化细菌溶细胞素的方法
US8048432B2 (en) * 2003-08-06 2011-11-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Polysaccharide-protein conjugate vaccines
US9173931B2 (en) * 2003-08-06 2015-11-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Process for preparing polysaccharide-protein conjugate vaccines
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
US20050118199A1 (en) * 2003-10-07 2005-06-02 Esser Mark T. Process for covalently conjugating polysaccharides to microspheres or biomolecules
JP2008506789A (ja) 2004-07-18 2008-03-06 シーエスエル、リミテッド インターフェロン−ガンマ応答強化を誘発するための免疫刺激複合体及びオリゴヌクレオチド処方物
US7709001B2 (en) 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
NZ562719A (en) 2005-04-08 2008-12-24 Wyeth Corp Separation of contaminants from streptococcus pneumoniae polysaccharide by pH manipulation
US20070184072A1 (en) 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
US7955605B2 (en) * 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
EP2425853A1 (en) 2005-04-08 2012-03-07 Wyeth LLC Multivalent Pneumococcal Polysaccharide-Protein Conjugate Composition
EA014107B1 (ru) * 2005-12-22 2010-10-29 Глаксосмитклайн Байолоджикалс С.А. Вакцина, содержащая конъюгаты капсульных полисахаридов streptococcus pneumoniae
AU2007284878B2 (en) * 2006-08-07 2013-01-17 President And Fellows Of Harvard College Protein matrix vaccines and methods of making and administering such vaccines
ATE473289T1 (de) 2006-10-10 2010-07-15 Wyeth Llc Verbesserte verfahren zur trennung von streptococcus pneumoniae-3-polysacchariden
CN101522218B (zh) * 2006-10-12 2012-09-26 葛兰素史密丝克莱恩生物有限公司 包含水包油乳液佐剂的疫苗
HUE039169T2 (hu) 2007-03-23 2018-12-28 Wyeth Llc Rövidített tisztítási eljárás Streptococcus pneumoniae tok-poliszacharidok elõállítására
ES2621359T3 (es) * 2007-06-20 2017-07-03 Pfizer Ireland Pharmaceuticals Polisacáridos modificados para vacunas conjugadas
US20100183662A1 (en) * 2007-06-26 2010-07-22 Ralph Leon Biemans Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
JP2011527579A (ja) * 2008-07-08 2011-11-04 アボット・ラボラトリーズ プロスタグランジンe2結合タンパク質およびこの使用
CA2757620C (en) 2009-04-30 2016-04-26 Coley Pharmaceutical Group, Inc. Pneumococcal vaccine and uses thereof
TW201136603A (en) * 2010-02-09 2011-11-01 Merck Sharp & Amp Dohme Corp 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition
GB201003924D0 (en) * 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
GB201003922D0 (en) * 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
KR20140005892A (ko) * 2010-12-10 2014-01-15 머크 샤프 앤드 돔 코포레이션 면역원성 조성물의 진탕-유도된 응집을 완화시키는 신규한 제제
GB201103836D0 (en) * 2011-03-07 2011-04-20 Glaxosmithkline Biolog Sa Conjugation process
GB201106225D0 (en) * 2011-04-13 2011-05-25 Glaxosmithkline Biolog Sa Fermentation process
KR102057217B1 (ko) * 2012-06-20 2020-01-22 에스케이바이오사이언스 주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
US9517274B2 (en) * 2012-08-16 2016-12-13 Pfizer Inc. Glycoconjugation processes and compositions
US9636392B2 (en) * 2012-09-07 2017-05-02 Sk Chemical Co., Ltd. Production method for capsular polysaccharide having pneumococcal serotype
GB201218660D0 (en) * 2012-10-17 2012-11-28 Glaxosmithkline Biolog Sa Immunogenic composition
US20140105927A1 (en) * 2012-10-17 2014-04-17 Glaxosmithkline Biologicals S.A. Immunogenic composition
US20140193451A1 (en) * 2012-10-17 2014-07-10 Glaxosmithkline Biologicals Sa Immunogenic composition
KR20140075201A (ko) * 2012-12-11 2014-06-19 에스케이케미칼주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
US10392420B2 (en) * 2012-12-20 2019-08-27 Pfizer Inc. Glycoconjugation process
ITMI20130142A1 (it) * 2013-01-31 2014-08-01 Biosynth Srl Vaccini glicoconiugati comprendenti unita' di base di un costrutto molecolare esprimente epitopi multipli incorporati
CA2937184A1 (en) * 2014-01-21 2015-07-30 Pfizer Inc. Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
RU2743793C1 (ru) * 2014-01-21 2021-02-26 Пфайзер Инк. Капсульные полисахариды Streptococcus pneumoniae и их конъюгаты
US11160855B2 (en) * 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
PT3096785T (pt) * 2014-01-21 2020-10-13 Pfizer Composições imunogénicas que compreendem antigénios de sacáridos capsulares conjugados e utilizações das mesmas
JP2017505792A (ja) * 2014-02-14 2017-02-23 ファイザー・インク 免疫原性糖タンパク質コンジュゲート
US9631328B2 (en) * 2014-03-12 2017-04-25 Permavoid Limited Sports field structure and modules and method for forming the same
MX395525B (es) * 2015-01-15 2025-03-25 Pfizer Composiciones inmunogenicas para usar en vacunas neumococicas.
TWI718144B (zh) * 2015-05-04 2021-02-11 美商輝瑞股份有限公司 B型鏈球菌多醣-蛋白質軛合物、製造軛合物之方法、含軛合物之免疫原性組成物、及其用途
MY192183A (en) * 2015-07-21 2022-08-05 Pfizer Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
US10751402B2 (en) * 2016-11-09 2020-08-25 Pfizer Inc. Immunogenic compositions and uses thereof
HRP20220573T1 (hr) * 2017-01-20 2022-06-10 Pfizer Inc. Imunogeni pripravci, namijenjeni upotrebi u pneumokoknim cjepivima
US11090374B2 (en) * 2017-02-24 2021-08-17 Merck Sharp & Dohme Corp. Enhancing immunogenicity of Streptococcus pneumoniae polysaccharide-protein conjugates
KR20250046326A (ko) * 2017-09-07 2025-04-02 머크 샤프 앤드 돔 엘엘씨 폐렴구균 폴리사카라이드 및 면역원성 폴리사카라이드-담체 단백질 접합체에서의 그의 용도
US11524076B2 (en) * 2017-09-07 2022-12-13 Merck Sharp & Dohme Llc Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
AU2018400751B2 (en) * 2017-12-06 2022-07-21 Merck Sharp & Dohme Llc Compositions comprising Streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof

Also Published As

Publication number Publication date
US20190000953A1 (en) 2019-01-03
US11426456B2 (en) 2022-08-30
IL270760A (en) 2020-01-30
DK3096783T3 (da) 2021-08-02
IL270764A (en) 2020-01-30
EP3957321A2 (en) 2022-02-23
IL270761A (en) 2020-01-30
HUE055408T2 (hu) 2021-12-28
WO2015110940A2 (en) 2015-07-30
PT3096783T (pt) 2021-08-16
EP3096783B1 (en) 2021-07-07
IL246652A0 (en) 2016-08-31
MX382438B (es) 2025-03-13
WO2015110940A3 (en) 2015-11-26
IL283554A (en) 2021-07-29
FR22C1039I2 (fr) 2023-05-26
IL270764B (en) 2021-04-29
MX371454B (es) 2020-01-29
AU2020204254B2 (en) 2022-06-02
AU2015208820A1 (en) 2016-07-14
CN120718167A (zh) 2025-09-30
JP6612260B2 (ja) 2019-11-27
SI3096783T1 (sl) 2021-09-30
HRP20211337T1 (hr) 2021-11-26
US20210023193A1 (en) 2021-01-28
IL270761B (en) 2021-04-29
JP2020109072A (ja) 2020-07-16
CN112168957A (zh) 2021-01-05
CN105934251A (zh) 2016-09-07
CA2937184A1 (en) 2015-07-30
BR112016015835A2 (pt) 2017-09-19
US20220378897A1 (en) 2022-12-01
IL270760B (en) 2021-06-30
AU2015208820B2 (en) 2020-05-14
EP3096783A2 (en) 2016-11-30
IL283554B (en) 2022-08-01
FR22C1039I1 (fr) 2022-09-09
PL3096783T3 (pl) 2021-12-13
JP6947788B2 (ja) 2021-10-13
RU2016126846A3 (es) 2018-02-28
RU2710393C2 (ru) 2019-12-26
JP6594581B2 (ja) 2019-10-23
KR102049826B1 (ko) 2019-12-03
HK1223273A1 (zh) 2017-07-28
ES2883343T3 (es) 2021-12-07
JP2020055810A (ja) 2020-04-09
US10105431B2 (en) 2018-10-23
JP2017504660A (ja) 2017-02-09
EP3957321A3 (en) 2022-07-13
RU2016126846A (ru) 2018-02-28
KR102099741B1 (ko) 2020-04-10
JP6947789B2 (ja) 2021-10-13
BR112016015835B1 (pt) 2023-12-26
US20160324948A1 (en) 2016-11-10
US12343389B2 (en) 2025-07-01
KR20160108539A (ko) 2016-09-19
KR20190132580A (ko) 2019-11-27
AU2020204254A1 (en) 2020-07-16
JP2019163312A (ja) 2019-09-26
US10918708B2 (en) 2021-02-16

Similar Documents

Publication Publication Date Title
MX2016009468A (es) Polisacaridos capsulares de streptococcus pneumoniae y conjugados de los mismos.
MX2016009469A (es) Polisacaridos capsulares de streptococcus pneumoniae y conjugados de los mismos.
ZA201807203B (en) Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
ZA201903620B (en) Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
IL265623A (en) Multivalent vaccines for pneumonia that include polysaccharide-protein conjugates
ZA201603925B (en) Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
EA033491B1 (ru) Конъюгатные вакцины на основе сальмонеллы
TN2019000064A1 (en) Composition comprising multivalent capsular polysaccharide-transport protein and use thereof
WO2015181834A3 (en) Novel semi-synthetic meningococcal conjugate vaccine
IL269028A (en) Boronized multifunctional drug-targeting conjugates, their uses and methods of preparation

Legal Events

Date Code Title Description
FG Grant or registration